Amylyx Pharmaceuticals, Inc. (AMLX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 92.45M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 27.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -162.10M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $92.45M | (m) | $27.90M | $-162.10M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $95.89M | (m) | $26.93M | $-159.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $90.40M | $0.00 | $27.64M | $-153.29M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $92.08M | $-665.00K | $28.00M | $-157.34M | (m) | -13847.07% | -4210.53% | (m) | (m) |
| 2025-06-30 | $93.47M | $-249.00K | $27.73M | $-196.97M | (m) | -37536.14% | -11135.34% | (m) | (m) |
| 2025-03-31 | $89.59M | $-1.27M | $29.95M | $-230.40M | (m) | -7043.63% | -2354.32% | (m) | (m) |
| 2024-12-31 | $104.08M | $87.37M | $33.04M | $-314.73M | (m) | 119.13% | 37.81% | (m) | (m) |
| 2024-09-30 | $126.11M | $196.49M | $35.83M | $-272.14M | (m) | 64.18% | 18.24% | (m) | (m) |
| 2024-06-30 | $134.91M | $298.76M | $39.20M | $-177.76M | (m) | 45.16% | 13.12% | (m) | (m) |
| 2024-03-31 | $140.60M | $398.00M | $39.58M | $-81.28M | (m) | 35.33% | 9.95% | (m) | (m) |
| 2023-12-31 | $128.19M | $380.79M | $37.16M | $38.80M | (m) | 33.66% | 9.76% | (m) | (m) |
| 2023-09-30 | $106.09M | $294.22M | $33.72M | $-7.72M | (m) | 36.06% | 11.46% | (m) | (m) |
| 2023-06-30 | $100.96M | $191.87M | $29.07M | $-81.13M | (m) | 52.62% | 15.15% | (m) | (m) |
| 2023-03-31 | $96.18M | (m) | $24.82M | $-155.58M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $93.45M | $22.23M | $21.71M | $-201.34M | (m) | 420.38% | 97.68% | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $44.04M | $285.00K | $3.14M | $-82.69M | (m) | 15452.63% | 1100.35% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |